(MedPage Today) — WASHINGTON — Semaglutide (Wegovy) improved liver inflammation and fibrosis in patients with metabolic dysfunction-associated steatohepatitis (MASH) through both weight loss-related and direct biological effects, according…
Source link : https://www.medpagetoday.com/meetingcoverage/aasld/118430
Author :
Publish date : 2025-11-10 22:07:00
Copyright for syndicated content belongs to the linked Source.
